Approval · Notice of Compliance 37412 · 2026
OMVOH: Notice of Compliance 37412
Issued April 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37412
- Date
- April 24, 2026
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternative maintenance dosing option for ulcerative colitis
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OMVOH | Not yet assigned | — |
Medicinal ingredients
- MIRIKIZUMAB 200 MG per 2ML
- MIRIKIZUMAB 200 MG per PEN